HLA-DPA1*02:01~B1*01:01 是原发性硬化性胆管炎的风险单倍型,介导 NKp44+ NK 细胞活化
研究在 3408 例原发性硬化性胆管炎(PSC)患者和 34213 名对照中分析 HLA-DP 单倍型,发现 HLA-DPA1*02:01~B1*01:01 与 PSC 风险升高相关(OR 1.99,p=6.7×10⁻⁵⁰)。功能实验显示该 HLA-DP 分子可结合活化受体 NKp44 并促进 NKp44+ NK 细胞脱颗粒,提示其在 PSC 发病中的作用。
要点
- PSC 患者肝内胆管 HLA-DP 表达升高,NKp44+ NK 细胞在肝脏富集。
- HLA-DPA1*02:01~B1*01:01 与 PSC 风险升高相关(OR 1.99,p=6.7×10⁻⁵⁰)。
- 该单倍型分子可结合 NKp44 并促进 NKp44+ NK 细胞脱颗粒。
核心结论
- 研究识别出新的 PSC 风险单倍型 HLA-DPA1*02:01~B1*01:01,并提供临床与功能数据提示识别胆管细胞所表达该分子的 NKp44+ NK 细胞参与 PSC 发病。
研究设计与样本
- 对 PSC 患者和对照者的肝组织、肝内及外周血淋巴细胞进行流式细胞术、免疫组化和免疫荧光分析。
- 在 3408 例 PSC 患者和 34213 名对照中进行 HLA-DPA1 和 HLA-DPB1 填充与关联分析。
- 体外使用板结合 HLA-DP 分子及 HLA-DPB 野生型与敲除的人胆管细胞类器官评估 NKp44/HLA-DP 相互作用对 NK 细胞活化的影响。
主要发现
- NKp44+ NK 细胞在肝脏富集,PSC 患者肝内胆管 HLA-DP 表达更高。
- HLA-DPA1*02:01~B1*01:01 的 PSC 风险显著升高(OR 1.99,p=6.7×10⁻⁵⁰)。
- 原代 NKp44+ NK 细胞对板结合 HLA-DPA1*02:01-DPB1*01:01 的脱颗粒反应显著高于对照 HLA-DP 分子,且可被抗 NKp44 阻断抑制。
- IFN-γ 暴露后表达 HLA-DPA1*02:01-DPB1*01:01 的人胆管细胞类器官与 NKp44-Fc 构建体结合较未刺激对照显著增加。
- 表达 HLA-DPA1*02:01-DPB1*01:01 的类器官较 HLA-DPB1 敲除类器官增加 NKp44+ NK 细胞脱颗粒。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary sclerosing cholangitis (PSC) is characterised by bile duct strictures and progressive liver disease, eventually requiring liver transplantation. Although the pathogenesis of PSC remains incompletely understood, strong associations with HLA-class II haplotypes have been described. As specific HLA-DP molecules can bind the activating NK-cell receptor NKp44, we investigated the role of HLA-DP/NKp44-interactions in PSC. DESIGN: Liver tissue, intrahepatic and peripheral blood lymphocytes of individuals with PSC and control individuals were characterised using flow cytometry, immunohistochemical and immunofluorescence analyses. HLA-DPA1 and HLA-DPB1 imputation and association analyses were performed in 3408 individuals with PSC and 34 213 controls. NK cell activation on NKp44/HLA-DP interactions was assessed in vitro using plate-bound HLA-DP molecules and HLA-DPB wildtype versus knock-out human cholangiocyte organoids. RESULTS: NKp44+NK cells were enriched in livers, and intrahepatic bile ducts of individuals with PSC showed higher expression of HLA-DP. HLA-DP haplotype analysis revealed a highly elevated PSC risk for HLA-DPA1*02:01~B1*01:01 (OR 1.99, p=6.7×10-50). Primary NKp44+NK cells exhibited significantly higher degranulation in response to plate-bound HLA-DPA1*02:01-DPB1*01:01 compared with control HLA-DP molecules, which were inhibited by anti-NKp44-blocking. Human cholangiocyte organoids expressing HLA-DPA1*02:01-DPB1*01:01 after IFN-γ-exposure demonstrated significantly increased binding to NKp44-Fc constructs compared with unstimulated controls. Importantly, HLA-DPA1*02:01-DPB1*01:01-expressing organoids increased degranulation of NKp44+NK cells compared with HLA-DPB1-KO organoids. CONCLUSION: Our studies identify a novel PSC risk haplotype HLA-DP A1*02:01~DPB1*01:01 and provide clinical and functional data implicating NKp44+NK cells that recognise HLA-DPA1*02:01-DPB1*01:01 expressed on cholangiocytes in PSC pathogenesis.
引用
- Zecher BF, Ellinghaus D, Schloer S, et al. HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. Gut. 2024. PMID: 37788895. doi:10.1136/gutjnl-2023-329524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。